Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a vaccine manufacturer funds clinical trials, secures government contracts, and discloses safety data can feel overwhelming. Sinovac Biotech’s filings span dense annual reports, rapid-fire 8-K updates, and daily insider trade notices—each packed with technical language on batch releases and regulatory milestones that investors can’t afford to miss.
Stock Titan eliminates that complexity. Our AI reviews every Sinovac Biotech quarterly earnings report 10-Q filing, annual report 10-K, and Form 4 the moment they hit EDGAR. The result: Sinovac Biotech SEC filings explained simply. Need to confirm cash burn for a new inactivated-virus program? Our AI summary highlights it. Want real-time alerts when executives buy or sell? Sinovac Biotech Form 4 insider transactions real-time arrive in your dashboard seconds after filing. You’ll also see any Sinovac Biotech 8-K material events explained with plain-language context so you understand implications fast.
Investors typically start with the Sinovac Biotech annual report 10-K simplified to gauge pipeline progress, then check the Sinovac Biotech proxy statement executive compensation for alignment between management pay and R&D success. For short-term trends, our platform layers AI insight onto each Sinovac Biotech earnings report filing analysis. And because insider sentiment matters, Sinovac Biotech insider trading Form 4 transactions and Sinovac Biotech executive stock transactions Form 4 are searchable, sortable, and exportable. From comprehensive coverage of all filing types to expert, AI-powered explanations, every disclosure you need to evaluate this vaccine leader is right here.
Schedule 13D/A Amendment No. 6 filed by Dr. Weidong Yin discloses continued beneficial ownership of 6,359,500 Sinovac Biotech (SVA) common shares, representing 8.85 % of the 71.86 million shares outstanding as reported in the company’s 2023 Form 20-F.
The amendment adds one material update: on 10 July 2025 Sinovac announced a newly constituted 10-member Board of Directors that now includes Dr. Yin. He has accepted the appointment and intends to participate in the issuer’s future governance. Aside from this governance change, Dr. Yin states he currently has no specific plans that would trigger any of clauses (a)–(j) of Item 4 (e.g., mergers, asset sales, recapitalisations). He continues conversations with other shareholders on governance and value-enhancing matters but expressly disclaims acting as a group.
- Ownership structure: Sole voting and dispositive power over the entire 6.36 million-share position; no shared power disclosed.
- Funding source: Personal funds (“PF”).
- Citizenship: China.
No new contracts or arrangements regarding the securities are reported beyond those described in Item 4. The filing is signed by Dr. Yin on 14 July 2025.
Vivo Capital VIII, LLC and Vivo Capital IX, LLC filed Amendment No. 6 to their Schedule 13D regarding Sinovac Biotech Ltd. (NASDAQ: SVA) on 11 July 2025. The filing updates share ownership and details an ongoing proxy and litigation battle over control of Sinovac’s board.
Ownership: Vivo Capital VIII reports 1,361,236 common shares (1.9%); Vivo Capital IX reports 4,541,764 common shares (6.3%), based on 71,860,702 shares outstanding, for a combined 8.2% economic interest. Both entities have shared voting and dispositive power over their respective holdings.
Purpose of transaction: The amendment narrates events surrounding a Special Meeting called for 8 July 2025. Sinovac sought a court injunction to exclude Vivo and another investor from voting. Vivo opposed the injunction; the Eastern Caribbean Court of Appeal stayed enforcement on 8 July, enabling Vivo to vote its shares by proxy in favor of SAIF’s director slate (including Mr. Shan Fu). Sinovac disclosed on 10 July 2025 that the SAIF-backed slate was elected and Mr. Fu joined the board.
Vivo states it will continue to engage with other shareholders and pursue actions under Item 4 of Schedule 13D, such as influencing board composition, dividend policy, auditor replacement, SEC filing compliance, and a potential NASDAQ relisting. Vivo also references multiple legal proceedings, including a 30 June 2025 U.S. District Court injunction compelling disclosure from shareholders linked to Sinovac’s chairman.
Exhibits: Two press releases (2 July 2025 and 9 July 2025) describing the legal developments are incorporated by reference.
Implications for investors: The filing confirms an activist position totaling 8.2% of Sinovac’s equity and outlines continuing efforts to reshape governance. While successful in electing a new board slate, persistent litigation indicates ongoing uncertainty around corporate control and future strategic direction.
Schedule 13D/A (Amendment No. 5) – Sinovac Biotech Ltd. (SVA) details the current ownership position and voting intentions of 1Globe Capital LLC and its affiliate 1Globe Biomedical (Hong Kong) Co. Ltd.
Ownership snapshot:
- Total beneficial ownership: 18,515,315 common shares, equal to 32.3 % of the outstanding shares (based on the 57.28 million share count from Sinovac’s 2018 20-F).
- Sole voting / dispositive power: 6,812,855 shares.
- Shared voting / dispositive power: 11,702,460 shares (primarily via CDH Utopia Ltd. and related parties).
Proxy contest stance: On 27 June 2025, Dr. Chiang Li (chairman of Sinovac and of both reporting entities) cast his 6.81 million directly-held shares “AGAINST” two proposals to (1) remove the current board (other than Dr. Li) and (2) install a new slate nominated by shareholder SAIF. 1Globe instructed affiliates to vote a further 11.7 million shares against both proposals, aligning roughly one-third of all votes with the incumbent board ahead of the 8 July 2025 special meeting.
Litigation & share-count dispute: Ownership percentages exclude “Exchange Shares” and the “Disputed PIPE” securities issued after May 2018, whose validity is being litigated. The reporting persons, alongside OrbiMed, are parties to multiple suits related to these issuances and prior corporate actions.
Governance implications: 1Globe’s 32 % block makes it difficult for dissident shareholders to secure a majority, increasing the probability that the existing board composition is maintained. Nevertheless, continuing legal challenges over share validity and control keep governance risk elevated and could influence future dilution, corporate actions, and strategic direction.
FAQ
What is the market cap of Sinovac Biotech (SVA)?
